KR20190007533A - 항바이러스성 화합물의 고체 형태 - Google Patents

항바이러스성 화합물의 고체 형태 Download PDF

Info

Publication number
KR20190007533A
KR20190007533A KR1020197001272A KR20197001272A KR20190007533A KR 20190007533 A KR20190007533 A KR 20190007533A KR 1020197001272 A KR1020197001272 A KR 1020197001272A KR 20197001272 A KR20197001272 A KR 20197001272A KR 20190007533 A KR20190007533 A KR 20190007533A
Authority
KR
South Korea
Prior art keywords
compound
bis
phosphate
hcl
tartrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197001272A
Other languages
English (en)
Korean (ko)
Inventor
올가 빅토로브나 라피나
빙 쉬
팡 왕
스코트 앨런 월켄하우어
Original Assignee
길리애드 파마셋 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리애드 파마셋 엘엘씨 filed Critical 길리애드 파마셋 엘엘씨
Publication of KR20190007533A publication Critical patent/KR20190007533A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020197001272A 2014-06-11 2015-06-08 항바이러스성 화합물의 고체 형태 Ceased KR20190007533A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010919P 2014-06-11 2014-06-11
US62/010,919 2014-06-11
PCT/US2015/034649 WO2015191431A1 (en) 2014-06-11 2015-06-08 Solid forms of an antiviral compound

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000696A Division KR20170015506A (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 고체 형태

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207036803A Division KR20200145852A (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 고체 형태

Publications (1)

Publication Number Publication Date
KR20190007533A true KR20190007533A (ko) 2019-01-22

Family

ID=53443009

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197001272A Ceased KR20190007533A (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 고체 형태
KR1020177000696A Ceased KR20170015506A (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 고체 형태
KR1020207036803A Ceased KR20200145852A (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 고체 형태

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177000696A Ceased KR20170015506A (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 고체 형태
KR1020207036803A Ceased KR20200145852A (ko) 2014-06-11 2015-06-08 항바이러스성 화합물의 고체 형태

Country Status (19)

Country Link
US (4) US9630972B2 (https=)
EP (3) EP3822275A1 (https=)
JP (3) JP2017517532A (https=)
KR (3) KR20190007533A (https=)
CN (1) CN106661042A (https=)
AR (1) AR103194A1 (https=)
AU (2) AU2015274961A1 (https=)
BR (1) BR112016028843A2 (https=)
CA (1) CA2951188C (https=)
EA (1) EA201692220A1 (https=)
ES (1) ES2785409T3 (https=)
IL (1) IL249041A0 (https=)
MX (1) MX2016016299A (https=)
PL (1) PL3154983T3 (https=)
PT (1) PT3154983T (https=)
SG (1) SG11201609810YA (https=)
SI (1) SI3154983T1 (https=)
TW (1) TWI721947B (https=)
WO (1) WO2015191431A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
SI2640719T1 (sl) 2010-11-17 2017-07-31 Gilead Pharmasset Llc Antivirusne spojine
JP6082749B2 (ja) 2011-11-16 2017-02-15 ギリアド ファーマセット エルエルシー 抗ウイルス化合物としての縮合イミダゾリルイミダゾール
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
JOP20170127A1 (ar) 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
CN108368123B (zh) * 2016-07-08 2021-02-19 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
CN106432253B (zh) * 2016-09-21 2019-06-14 上海众强药业有限公司 一种维帕他韦新晶型及其制备方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JPWO2004089933A1 (ja) * 2003-04-02 2006-07-06 アステラス製薬株式会社 フルオロベンズアミド誘導体の新規結晶
KR101164070B1 (ko) 2003-05-09 2012-07-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
EP1799685B1 (en) * 2004-09-22 2012-03-28 Pfizer Inc. Polymorphic forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
AU2007248282B2 (en) 2006-05-05 2011-12-08 Merck Patent Gmbh Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2009286694A (ja) * 2006-09-07 2009-12-10 Eisai R & D Management Co Ltd ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶
CA2823981C (en) 2006-12-07 2016-05-17 Daiichi Sankyo Company, Limited Film-coated preparation having improved stability
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5282037B2 (ja) * 2007-08-10 2013-09-04 田辺三菱製薬株式会社 新規なイソキノリン化合物の塩及びその結晶
ATE551337T1 (de) 2008-02-12 2012-04-15 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
HRP20120706T1 (hr) 2008-02-13 2012-09-30 Bristol-Myers Squibb Company Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2732777A1 (en) 2008-08-07 2010-02-11 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
SI2373172T1 (sl) 2008-12-03 2013-12-31 Presidio Pharmaceuticals, Inc. Inhibitorji HCV NS5A
WO2010065668A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
WO2010111673A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
SG174883A1 (en) 2009-03-27 2011-11-28 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
SG174929A1 (en) 2009-03-27 2011-11-28 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
WO2010132538A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
PT3309157T (pt) 2009-05-13 2019-12-02 Gilead Pharmasset Llc Compostos antivirais
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201290089A1 (ru) 2009-09-04 2012-09-28 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Химические соединения
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
EA201290882A1 (ru) 2010-03-09 2013-04-30 Мерк Шарп Энд Домэ Корп. Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
BR112013004520A2 (pt) 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
SG188618A1 (en) 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
SI2640719T1 (sl) 2010-11-17 2017-07-31 Gilead Pharmasset Llc Antivirusne spojine
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
JP6082749B2 (ja) 2011-11-16 2017-02-15 ギリアド ファーマセット エルエルシー 抗ウイルス化合物としての縮合イミダゾリルイミダゾール
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
HK1201186A1 (en) 2011-12-29 2015-08-28 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
TW201434949A (zh) 2013-01-31 2014-09-16 Nitto Denko Corp 環氧組合物及環氧樹脂成形體
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
JP2016051146A (ja) 2014-09-02 2016-04-11 ウシオ電機株式会社 光検出装置
EP3588013A1 (de) 2018-06-26 2020-01-01 XelectriX Power GmbH Verfahren zur abgabe von elektrischer energie

Also Published As

Publication number Publication date
JP2017517532A (ja) 2017-06-29
IL249041A0 (en) 2017-01-31
CA2951188A1 (en) 2015-12-17
US9630972B2 (en) 2017-04-25
US20170247386A1 (en) 2017-08-31
SI3154983T1 (sl) 2020-04-30
EA201692220A1 (ru) 2017-05-31
AU2018201948A1 (en) 2018-04-12
ES2785409T3 (es) 2020-10-06
TW201609745A (zh) 2016-03-16
SG11201609810YA (en) 2016-12-29
AR103194A1 (es) 2017-04-26
US11203599B2 (en) 2021-12-21
MX2016016299A (es) 2017-04-06
US20190270750A1 (en) 2019-09-05
EP3154983A1 (en) 2017-04-19
BR112016028843A2 (pt) 2017-08-22
KR20200145852A (ko) 2020-12-30
CA2951188C (en) 2019-09-24
JP2019172711A (ja) 2019-10-10
EP3666775A1 (en) 2020-06-17
EP3154983B1 (en) 2020-02-12
US20200283449A1 (en) 2020-09-10
US10604530B2 (en) 2020-03-31
PL3154983T3 (pl) 2020-06-29
US20150361085A1 (en) 2015-12-17
KR20170015506A (ko) 2017-02-08
EP3822275A1 (en) 2021-05-19
PT3154983T (pt) 2020-05-06
AU2018201948B2 (en) 2019-10-03
JP2019070057A (ja) 2019-05-09
TWI721947B (zh) 2021-03-21
CN106661042A (zh) 2017-05-10
AU2015274961A1 (en) 2016-12-01
WO2015191431A1 (en) 2015-12-17
US9884873B2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
KR20190007533A (ko) 항바이러스성 화합물의 고체 형태
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
US9409891B2 (en) Solid forms of an antiviral compound
KR20150028971A (ko) 항바이러스성 화합물의 고체 형태
KR20250128379A (ko) 보체인자 b의 억제제
JP2018504414A (ja) ジヒドロピリミジン誘導体の複合体及び塩並びにそれらの医薬品への応用
KR102912761B1 (ko) [(1S)-1-[(2S,4R,5R)-5-(5-아미노-2-옥소-티아졸로[4,5-d]피리미딘-3-일)-4-하이드록시-테트라하이드로퓨란-2-일]프로필]아세테이트의 고체 형태
EP3766880B1 (en) Solid form of dihydropyrimidine compound and preparation method therefor and use thereof
HK40031882A (en) Solid forms of an antiviral compound
CN111601793B (zh) 苯并二环烷烃衍生物的药学上可接受的盐及其多晶型物及其应用
HK1237346A1 (en) Solid forms of an antiviral compound
JP7620711B2 (ja) アミドオキサゾール系化合物
TWI906614B (zh) 某些mcl-1抑制劑之鹽及同質多形體
HK1236199B (en) Solid forms of an antiviral compound
HK1236199A1 (en) Solid forms of an antiviral compound
JP2007505071A (ja) 結晶多形性ヌクレオシド化合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190114

Application number text: 1020177000696

Filing date: 20170110

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200605

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200617

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201120

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200617

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20201221

Application number text: 1020177000696

Filing date: 20170110

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20201223

WITB Written withdrawal of application